Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in ALS
NCT00561366Phase 2Withdrawn
- Sponsor
- LadRx
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Placebo with Arimoclomol (2 arms). Primary endpoint: Revised ALS Functional Rating Scale at 9 months. Status: withdrawn.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00561366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561366.